Longeveron Earnings Call Transcripts
Fiscal Year 2025
-
Secured $15M in new capital, extending cash runway into Q4 2026, while advancing pivotal HLHS and PDCM trials. Revenue fell 50% year-over-year, and net loss widened to $22.7M, but strategic partnerships and PRV opportunities could drive future growth.
-
Revenue declined 53% year-over-year due to lower demand, while net loss rose 45% as R&D and G&A expenses increased. Cash runway extends into late Q1 2026, with pivotal HLHS trial results expected in Q3 2026 and BLA filing now targeted for 2027.
-
Advanced pivotal HLHS trial with BLA submission targeted for late 2026, expanded pipeline to pediatric DCM, and secured FDA alignment for key programs. Revenue declined 31% year-over-year, with increased R&D and G&A expenses; cash runway extends into Q1 2026, pending further financing.
-
The meeting covered director election, incentive plan amendment, and auditor ratification, with all proposals approved by majority vote. Stockholders participated virtually, and voting results will be reported on Form 8-K. Questions from stakeholders will be addressed online.
-
Q1 2025 revenue declined 30% year-over-year to $0.4M, with net loss rising to $5.0M and cash of $14.3M. HLHS and Alzheimer's programs advanced toward pivotal milestones, including near-complete ELPIS II enrollment and regulatory alignment for a single adaptive Alzheimer's trial.
-
The company is advancing allogeneic stem cell therapies, prioritizing HLHS with a pivotal phase IIb trial nearing full enrollment and aiming for a BLA filing in 2026. Manufacturing capacity meets global demand, and commercialization will focus on top academic centers. Alzheimer's program holds RMAT status, with an accelerated FDA path under discussion.
-
Advancing stem cell therapy programs, the lead asset has shown strong safety and efficacy in HLHS, Alzheimer's, and frailty trials. Regulatory designations and a clear FDA roadmap support plans for a BLA submission next year, targeting major markets and unmet needs.
-
Lomecel-B, an allogeneic stem cell therapy, is advancing in pivotal trials for HLHS and Alzheimer's, with strong safety and efficacy signals and multiple FDA designations. The company is financially stable through early 2026 and prioritizes these high-value programs.
Fiscal Year 2024
-
Lomecel-B advanced in pivotal HLHS and Alzheimer's trials, with strong regulatory momentum and 237% revenue growth in 2024. BLA submission for HLHS is targeted for 2026, with increased spending and additional funding anticipated for commercial readiness.
-
Lomecel-B has demonstrated positive results in HLHS, Alzheimer's, and frailty, with pivotal trials advancing and strong FDA support. The company is preparing for a BLA submission in early 2026 for HLHS and pursuing partnerships for Alzheimer's, targeting large market opportunities.
-
Strong clinical and regulatory progress for Lomecel-B in HLHS and Alzheimer's, with positive trial data, multiple FDA designations, and improved financials. Revenue rose 177% year-over-year, and cash runway extends through Q4 2025.
-
Lomecel-B advanced in HLHS and Alzheimer's, with key regulatory designations and strong clinical data. Revenue doubled year-over-year, expenses declined, and cash runway extends through Q4 2025. Contract manufacturing is scaling, targeting $4–$5 million annual revenue.
-
Shareholders elected four directors for three-year terms, approved an amendment to the 2021 Incentive Award Plan, and ratified the appointment of Marcum LLP as auditors. Voting results will be filed with the SEC, and shareholder questions will be addressed online.